Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. / Bouazzi, Meyya; Bak, Nina F.; Agnholt, Jørgen; Wewer, Vibeke; Malham, Mikkel; Bendix, Mia.

I: GastroHep, Bind 2022, 9550908, 2022, s. 1-11.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bouazzi, M, Bak, NF, Agnholt, J, Wewer, V, Malham, M & Bendix, M 2022, 'Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment', GastroHep, bind 2022, 9550908, s. 1-11. https://doi.org/10.1155/2022/9550908

APA

Bouazzi, M., Bak, N. F., Agnholt, J., Wewer, V., Malham, M., & Bendix, M. (2022). Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. GastroHep, 2022, 1-11. [9550908]. https://doi.org/10.1155/2022/9550908

Vancouver

Bouazzi M, Bak NF, Agnholt J, Wewer V, Malham M, Bendix M. Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. GastroHep. 2022;2022:1-11. 9550908. https://doi.org/10.1155/2022/9550908

Author

Bouazzi, Meyya ; Bak, Nina F. ; Agnholt, Jørgen ; Wewer, Vibeke ; Malham, Mikkel ; Bendix, Mia. / Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. I: GastroHep. 2022 ; Bind 2022. s. 1-11.

Bibtex

@article{90e4306cf08540349ae5a261806826c0,
title = "Paediatric Crohn{\textquoteright}s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment",
abstract = "Background. Recent epidemiological studies in inflammatory bowel disease (IBD) indicate that paediatric onset of IBD (pIBD) more often requires biological therapy compared to adult onset of IBD (aIBD). Whether this is due to a more aggressive disease phenotype or lower threshold of prescribing biologicals is unknown. In order to expand these findings in a clinical setting, we compared the inflammatory burden in pIBD and aIBD patients requiring biological therapy. Methods. We retrospectively included 70 pIBD and 83 aIBD patients initiating biological therapy. Symptoms and biomarker levels were recorded prior to and 6, 14, 22, and 52 weeks after initiation of biological therapy. Results. In Crohn{\textquoteright}s disease (CD), the baseline levels of faecal calprotectin and C-reactive protein (CRP) were increased in paediatric CD patients compared to adult CD patients ( and , respectively). No significant differences were seen in ulcerative colitis (UC). In CD, baseline vitamin D  nmol/L and baseline CRP  mg/L were associated with higher remission rate () at the end of follow-up. Moreover, aIBD patients had a higher risk of loss of response to biological therapy and treatment discontinuation compared to pIBD patients ( [1.6-13.4], ). Conclusions. pCD patients had increased inflammation markers compared to aCD patients prior to biological treatment. In addition to this,  nmol/L and high CRP levels predicted poor response to treatment in IBD patients.",
author = "Meyya Bouazzi and Bak, {Nina F.} and J{\o}rgen Agnholt and Vibeke Wewer and Mikkel Malham and Mia Bendix",
year = "2022",
doi = "10.1155/2022/9550908",
language = "English",
volume = "2022",
pages = "1--11",
journal = "GastroHep",
issn = "1478-1239",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment

AU - Bouazzi, Meyya

AU - Bak, Nina F.

AU - Agnholt, Jørgen

AU - Wewer, Vibeke

AU - Malham, Mikkel

AU - Bendix, Mia

PY - 2022

Y1 - 2022

N2 - Background. Recent epidemiological studies in inflammatory bowel disease (IBD) indicate that paediatric onset of IBD (pIBD) more often requires biological therapy compared to adult onset of IBD (aIBD). Whether this is due to a more aggressive disease phenotype or lower threshold of prescribing biologicals is unknown. In order to expand these findings in a clinical setting, we compared the inflammatory burden in pIBD and aIBD patients requiring biological therapy. Methods. We retrospectively included 70 pIBD and 83 aIBD patients initiating biological therapy. Symptoms and biomarker levels were recorded prior to and 6, 14, 22, and 52 weeks after initiation of biological therapy. Results. In Crohn’s disease (CD), the baseline levels of faecal calprotectin and C-reactive protein (CRP) were increased in paediatric CD patients compared to adult CD patients ( and , respectively). No significant differences were seen in ulcerative colitis (UC). In CD, baseline vitamin D  nmol/L and baseline CRP  mg/L were associated with higher remission rate () at the end of follow-up. Moreover, aIBD patients had a higher risk of loss of response to biological therapy and treatment discontinuation compared to pIBD patients ( [1.6-13.4], ). Conclusions. pCD patients had increased inflammation markers compared to aCD patients prior to biological treatment. In addition to this,  nmol/L and high CRP levels predicted poor response to treatment in IBD patients.

AB - Background. Recent epidemiological studies in inflammatory bowel disease (IBD) indicate that paediatric onset of IBD (pIBD) more often requires biological therapy compared to adult onset of IBD (aIBD). Whether this is due to a more aggressive disease phenotype or lower threshold of prescribing biologicals is unknown. In order to expand these findings in a clinical setting, we compared the inflammatory burden in pIBD and aIBD patients requiring biological therapy. Methods. We retrospectively included 70 pIBD and 83 aIBD patients initiating biological therapy. Symptoms and biomarker levels were recorded prior to and 6, 14, 22, and 52 weeks after initiation of biological therapy. Results. In Crohn’s disease (CD), the baseline levels of faecal calprotectin and C-reactive protein (CRP) were increased in paediatric CD patients compared to adult CD patients ( and , respectively). No significant differences were seen in ulcerative colitis (UC). In CD, baseline vitamin D  nmol/L and baseline CRP  mg/L were associated with higher remission rate () at the end of follow-up. Moreover, aIBD patients had a higher risk of loss of response to biological therapy and treatment discontinuation compared to pIBD patients ( [1.6-13.4], ). Conclusions. pCD patients had increased inflammation markers compared to aCD patients prior to biological treatment. In addition to this,  nmol/L and high CRP levels predicted poor response to treatment in IBD patients.

U2 - 10.1155/2022/9550908

DO - 10.1155/2022/9550908

M3 - Journal article

VL - 2022

SP - 1

EP - 11

JO - GastroHep

JF - GastroHep

SN - 1478-1239

M1 - 9550908

ER -

ID: 344851795